Artificial neural network-based inference of drug-target interactions

Siyabonga Melamane; Tavonga T. Manadava; Arthur Manda; Nonhlanhla Luphade; Sandile M.M. Khamanga; Pedzisai A. Makoni; Patrick H. Demana; Scott K. Matafwali; Bwalya A. Witika

doi:10.1016/B978-0-323-91763-6.00015-1

Artificial neural network-based inference of drug-target interactions

Siyabonga Melamane, Tavonga T. Manadava, Arthur Manda, Nonhlanhla Luphade, Sandile M.M. Khamanga, Pedzisai A. Makoni, Patrick H. Demana, Scott K. Matafwali, Bwalya A. Witika

Pharmaceutical Sciences

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

1 Citation (Scopus)

Abstract

The emergence of resistant superbugs, as well as new pandemics, has necessitated the need for the development of more efficient processes. Traditionally, the process can be very long and have a very high cost. Some of these costs and time constraints are a direct consequence of the prediction of drug-target interactions (DTI). It is of utmost importance to develop medicines whose interaction with their target can be performed cost-effectively and at breakneck speed. Artificial intelligence (AI) has made this highly possible and effective. One of the more useful aspects of AI is artificial neural networks (ANNs). ANNs make use of a simulated trainable brain capable of performing nonparametric tasks that do not assume an a priori relationship between the variables investigated and the dataset. In this chapter, we discuss the various roles of ANNs in prediction and value in DTI to improve drug discovery and repurposing.

Original language	English
Title of host publication	Nanotechnology Principles in Drug Targeting and Diagnosis
Publisher	Elsevier
Pages	35-62
Number of pages	28
ISBN (Electronic)	9780323917636
ISBN (Print)	9780323983488
DOIs	https://doi.org/10.1016/B978-0-323-91763-6.00015-1
Publication status	Published - 1 Jan 2023

Keywords

Artificial neural networks
drug development
drug discovery
drug repurposing
drug-target interactions

Access to Document

10.1016/B978-0-323-91763-6.00015-1

Cite this

@inbook{cfc72fb6e2f14329b2cf31a72304ae12,

title = "Artificial neural network-based inference of drug-target interactions",

abstract = "The emergence of resistant superbugs, as well as new pandemics, has necessitated the need for the development of more efficient processes. Traditionally, the process can be very long and have a very high cost. Some of these costs and time constraints are a direct consequence of the prediction of drug-target interactions (DTI). It is of utmost importance to develop medicines whose interaction with their target can be performed cost-effectively and at breakneck speed. Artificial intelligence (AI) has made this highly possible and effective. One of the more useful aspects of AI is artificial neural networks (ANNs). ANNs make use of a simulated trainable brain capable of performing nonparametric tasks that do not assume an a priori relationship between the variables investigated and the dataset. In this chapter, we discuss the various roles of ANNs in prediction and value in DTI to improve drug discovery and repurposing.",

keywords = "Artificial neural networks, drug development, drug discovery, drug repurposing, drug-target interactions",

author = "Siyabonga Melamane and Manadava, {Tavonga T.} and Arthur Manda and Nonhlanhla Luphade and Khamanga, {Sandile M.M.} and Makoni, {Pedzisai A.} and Demana, {Patrick H.} and Matafwali, {Scott K.} and Witika, {Bwalya A.}",

year = "2023",

month = jan,

day = "1",

doi = "10.1016/B978-0-323-91763-6.00015-1",

language = "English",

isbn = "9780323983488",

pages = "35--62",

booktitle = "Nanotechnology Principles in Drug Targeting and Diagnosis",

publisher = "Elsevier",

address = "Netherlands",

}

TY - CHAP

T1 - Artificial neural network-based inference of drug-target interactions

AU - Melamane, Siyabonga

AU - Manadava, Tavonga T.

AU - Manda, Arthur

AU - Luphade, Nonhlanhla

AU - Khamanga, Sandile M.M.

AU - Makoni, Pedzisai A.

AU - Demana, Patrick H.

AU - Matafwali, Scott K.

AU - Witika, Bwalya A.

PY - 2023/1/1

Y1 - 2023/1/1

N2 - The emergence of resistant superbugs, as well as new pandemics, has necessitated the need for the development of more efficient processes. Traditionally, the process can be very long and have a very high cost. Some of these costs and time constraints are a direct consequence of the prediction of drug-target interactions (DTI). It is of utmost importance to develop medicines whose interaction with their target can be performed cost-effectively and at breakneck speed. Artificial intelligence (AI) has made this highly possible and effective. One of the more useful aspects of AI is artificial neural networks (ANNs). ANNs make use of a simulated trainable brain capable of performing nonparametric tasks that do not assume an a priori relationship between the variables investigated and the dataset. In this chapter, we discuss the various roles of ANNs in prediction and value in DTI to improve drug discovery and repurposing.

AB - The emergence of resistant superbugs, as well as new pandemics, has necessitated the need for the development of more efficient processes. Traditionally, the process can be very long and have a very high cost. Some of these costs and time constraints are a direct consequence of the prediction of drug-target interactions (DTI). It is of utmost importance to develop medicines whose interaction with their target can be performed cost-effectively and at breakneck speed. Artificial intelligence (AI) has made this highly possible and effective. One of the more useful aspects of AI is artificial neural networks (ANNs). ANNs make use of a simulated trainable brain capable of performing nonparametric tasks that do not assume an a priori relationship between the variables investigated and the dataset. In this chapter, we discuss the various roles of ANNs in prediction and value in DTI to improve drug discovery and repurposing.

KW - Artificial neural networks

KW - drug development

KW - drug discovery

KW - drug repurposing

KW - drug-target interactions

UR - http://www.scopus.com/inward/record.url?scp=85176306653&partnerID=8YFLogxK

U2 - 10.1016/B978-0-323-91763-6.00015-1

DO - 10.1016/B978-0-323-91763-6.00015-1

M3 - Chapter

AN - SCOPUS:85176306653

SN - 9780323983488

SP - 35

EP - 62

BT - Nanotechnology Principles in Drug Targeting and Diagnosis

PB - Elsevier

ER -

Artificial neural network-based inference of drug-target interactions

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this